Montelukast Use Decreases Cardiovascular Events in Asthmatics
Cysteinyl leukotrienes are proinflammatory mediators with a clinically established role in asthma and a human genetic and preclinical role in cardiovascular pathology. Given that cardiovascular disease has a critical inflammatory component, the aim of this work was to conduct an observational study...
Main Authors: | Malvina Hoxha, Calogero C. Tedesco, Silvana Quaglin, Visar Malaj, Linda Pustina, Valerie Capra, Jilly F. Evans, Angelo Sala, G. Enrico Rovati |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.611561/full |
Similar Items
-
The Efficacy of Montelukast Monotherapy in Moderate Persistent Asthmatic Children
by: Mahir Igde, et al.
Published: (2009-09-01) -
Pediatric Asthma: Where Has Montelukast Gone?
by: Marco Maglione, et al.
Published: (2023-03-01) -
Montelukast Improves Symptoms and Lung Function in Asthmatic Women Compared With Men
by: Renata Esposito, et al.
Published: (2019-09-01) -
Expert opinion on montelukast and acebrophylline combination in the management of asthma
by: N H Krishna, et al.
Published: (2021-01-01) -
Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma
by: Scaparrotta Alessandra, et al.
Published: (2012-07-01)